Pharmaceuticals
I-MAB Filed 2022 Annual Report on Form 20-F
GAITHERSBURG, Md. and SHANGHAI, May 1, 2023 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it has filed its annual report on Form 20...
2023-05-01 20:00
2143
OBiO and CHINAGENE reached a strategic agreement of commercial manufacturing services for gene therapy products
SHANGHAI, April 29, 2023 /PRNewswire/ -- On April 21, 2023, OBiO Technology ( Shanghai) Corp., Ltd. (OBiO) announced a strategic agreement of commercial manufacturing collaboration with CHINAGENE. Under the agreement, OBiO will provide holistic contract development and manufacturing services to CH...
2023-04-29 23:20
4322
IMG-004 demonstrated extended half-life and durable pharmacodynamic characteristics in a Phase 1 study
SAN DIEGO, SHANGHAI and SYDNEY, April 28, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") today announced positive topline results from a Phase 1 study evaluating IMG-004 in healthy participants. IMG-004 is a potent, non-covalent, reversible, and brain permeable third-generation Br...
2023-04-28 17:00
1866
WuXi Biologics Releases 2022 ESG Report Detailing Its Continued Commitment to Sustainability
* The Report outlines new goals of net-zero GHG emissions across all operations by 2050 and a 10% reduction of waste intensity by 2027 compared with 2022. * The Company makes remarkable progress on environmental goals, achieving its water consumption intensity-reduction target in 2022, well a...
2023-04-28 14:43
2955
Daewoong Pharmaceutical announces a Global License Agreement for DWP213388, a new drug candidate for autoimmune disease with Vitalli Bio
- Exclusive rights for the development and commercialization of DWP213388 in the global market to Vitalli Bio, a portfolio company of Aditum Bio, the biotech investment firm - Targeting the KRW 146 trillion global autoimmune disease market with partner who has top global drug development expertis...
2023-04-28 08:58
2137
Ubie signs a broad collaboration agreement with Takeda Pharmaceuticals to promote digital transformation
- Aims to guide patients with rare and gastrointestinal diseases to appropriate medical care 〜Ubie will build on its achievements in the early detection of HAE and expand its collaboration with Takeda Pharmaceuticals to benefit patients in broader disease areas〜 NEW YORK, April 27, 2023 /PRNews...
2023-04-27 23:00
1881
Yuyu Pharma, Dry Eye Pipeline Mechanism of Action and Pre-clinical Results Published
SEOUL, South Korea, April 27, 2023 /PRNewswire/ -- At ARVO 2023, Yuyu Pharma unveiled the results of its mechanism of action and head-to- head studies for its dry eye treatment peptide (project name: YP-P10). ARVO is the world's largest ophthalmic society and held its annual meeting inNew Orleans...
2023-04-27 21:00
2070
ASCO 2023 | Ascentage Pharma to Present Results from 4 Studies Highlighting Extended Therapeutic Potential of Lead Drug Candidates
SUZHOU, China, and ROCKVILLE, MD, April 27, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that results from four clinical studies of the c...
2023-04-27 17:44
1813
Qilian Received a Letter from Nasdaq Related to Regain Compliance
JIUQUAN, China, April 26, 2023 /PRNewswire/ -- Qilian International Holding GroupLimited (NASDAQ: QLI) ("Qilian" or the "Company"), a China-based pharmaceutical and chemical products manufacturer, previously announced that on February 16, 2023, it received a written notice (the "Notice") from the ...
2023-04-27 05:00
2385
Fosun Pharma Develops Innovative Artemisinin-based Antimalarial Drugs Contributing to the Efforts for A Malaria-free World Through the Belt and Road Initiative
SHANGHAI, April 26, 2023 /PRNewswire/ -- On April 25, 2023, World Health Organization (WHO) gave as the theme for World Malaria Day 2023 Time to deliver zero malaria: invest, innovate, implement. Within this theme, WHO will mainly focus on the third "i" – implement – and notably the critical imp...
2023-04-26 22:32
3722
Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F at 2023 ASCO Annual Meeting
SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, April 26, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment o...
2023-04-26 22:15
3070
I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023
GAITHERSBURG, Md. and SHANGHAI, April 26, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that a poster featuring the latest clinical data of ul...
2023-04-26 21:16
2896
BIORCHESTRA Scientific Founder, Chairman, and Chief Executive Officer Joins the Republic of Korea (ROK) Official State Visit to the United States
* The Official State visit by the President of the Republic of Korea marks the 70th anniversary of the U.S.-ROK alliance, which is advancing peace, stability, and prosperity for the two countries, for theAsia-Pacific region, and globally * President Yoon Suk Yeol and First Lady Kim Keon Hee o...
2023-04-25 20:00
1506
Nippon Express (UK) Receives IATA CEIV Pharma Certification for Its Facility in Heathrow Airport Suburb
TOKYO, April 25, 2023 /PRNewswire/ -- Nippon Express (UK) Ltd. (hereinafter "NXUK"), a group company of NIPPON EXPRESS HOLDINGS, INC., has been awarded IATA CEIV Pharma certification*, a quality certificate for pharmaceutical transport established by the International Air Transport Association (I...
2023-04-25 15:00
1945
I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon
* Award is an important victory for I-Mab and its shareholders on multiple levels, ending the multi-year long dispute * Tribunal completely denied Tracon's groundless damages claim of over $200 million relating to I-Mab's next-generation bi-specific antibody assets and awarded no damages to T...
2023-04-25 13:46
1819
Ascentage Pharma Passes GMP Compliance Audit by EU QP with Zero Deficiency, in an Achievement Signaling Global Recognition of the Company's Quality Management System
SUZHOU, China and ROCKVILLE, Md., April 24, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it recently received a zero-deficiency repor...
2023-04-25 08:42
1848
I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China
GAITHERSBURG, Md. and SHANGHAI, April 24, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the first patient in a Phase 3 registrational tri...
2023-04-24 21:00
1928
BIORCHESTRA Announces Significant Progress in Studies of BMD-001 Drug Program
* Encouraging non-human primate (NHP) findings support the progression of IV-formulatedBMD-001 ahead of formal clinical studies for Alzheimer's disease, Amyotrophic Lateral Sclerosis, and Parkinson's disease * Further validation of Brain Targeting RNAi Nanomedicine (BTRiNTM), including target...
2023-04-24 20:00
1399
Four innovative drugs launched in three years, HKEX -Listed Simcere Pharmaceutical Group is on the Fast Track Toward Building an Innovation-Driven Global Pharmaceutical Company
-The revenue from innovative drugs accounted for more than 65% of total revenue -Simcere's total revenue and the revenue from innovative drugs hit record highs. NANJING, China, April 24, 2023 /PRNewswire/ -- On Apr. 18, Simcere Pharmaceutical (2096.HK) disclosed the latest progress on the compa...
2023-04-24 18:09
2398
Tibetan medicine advanced over past decade
BEIJING, April 24, 2023 /PRNewswire/ -- A news report from chinadaily.com.cn: Adhering to an equal emphasis on traditional Chinese and Western medicine, the government of the Tibet autonomous region has increased financial investment, formulated supportive policies and promoted the development of...
2023-04-24 17:04
1389
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
7433
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
6834
